CTLA-4 Blockade following Relapse of Malignancy after Allogeneic Stem Cell Transplantation Is Associated with T Cell Activation But Not with Increased Levels of T Regulatory Cells

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 5, 2011, Pages 682-692

  Zhou, Jiehua ^a   Bashey, Asad ^b   Zhong, Ruikun ^a   Corringham, Sue ^a   Messer, Karen ^a   Pu, Minya ^a   Ma, Wenxue ^a   Chut, Theresa ^a   Soiffer, Robert ^c   Mitrovich, Rachel C ^c   Lowy, Israel ^d   Ball, Edward D ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b NORTHSIDE HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MEDAREX INC   (United States)

Author keywords

Ipilimumab; T lymphocytes

Indexed keywords

CD45RO ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR ANTIGEN; IPILIMUMAB; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CD4+ CD25+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CD8-POSITIVE T-LYMPHOCYTES; CELL COUNT; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LECTINS, C-TYPE; LEUKEMIA; LYMPHOCYTE ACTIVATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; RECURRENCE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 79954592646     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.08.005     Document Type: Article

References (43)

1. Mielcarek M., Storer B.E., Flowers M.E., et al. Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1160-1168.
2. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007, 25:267-296.
3. Jonuleit H., Schmitt E., Stassen M., et al. Identification and functional characterization of human CD4+CD25+ T cells with regulatory properties isolated from peripheral blood. J Exp Med 2001, 193:1285-1294.
4. Zhang L., Zhao Y. The regulation of Foxp3 expression in regulatory CD4+CD25+ T cells: multiple pathways on the road. J Cell Physiol 2007, 211:590-597.
5. Teft W.A., Kirchhof M.G., Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006, 24:65-97.
6. Corthay A. How do regulatory T cells work?. Scand J Immunol 2009, 70:326-336.
7. Viguier M., Lemaitre F., Verola O., et al. Foxp3-expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004, 173:1444-1453.
8. Cai S., Cao X., Hassan A., et al. Granzyme B is not required for regulatory T cell-mediated suppression of graft-versus-host disease. Blood 2010, 115:1669-1677.
9. Kosmaczewska A., Ciszak L., Potoczek S., et al. The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp 2008, 56:181-191.
10. Yamaguchi T., Sakaguchi S. Regulator T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006, 16:115-123.
11. Leen A.M., Rooney C.M., Foster A.E. Improving T cell therapy for cancer. Annu Rev Immunol 2007, 25:243-265.
12. Beyer M., Schultze J.L. Regulatory T cells in cancer. Blood 2006, 108:804-811.
13. Sinicrope F.A., Rego R.L., Ansell S.M., et al. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009, 137:1270-1279.
14. Review Weber J. Anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007, 12:864-872.
15. Keilholz U. CTLA-4: negative regulator of the immune response and a target for cancer therapy. J Immunother 2008, 31:431-439.
16. Movva S., Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MXD-010): a novel treatment strategy in cancer management. Expert Opin Biol Ther 2009, 9:231-241.
17. Agarwala S.S. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen 4 blockade in advanced melonoma. Melanoma Res 2010, 20:1-10.
18. Sun J., Schiffman J., Raghunath A., et al. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 2008, 8:9-13.
19. Kavanagh B., O'Brien S., Lee D., et al. CTLA-4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 2008, 112:1175-1183.
20. Maker A.V., Attia P., Rosenberg S.A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol 2005, 175:7746-7754.
21. Fong L., Kwek S.S., O'Brien S., et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009, 69:609-615.
22. Fevery S., Billiau A.D., Sprangers B., et al. CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia 2007, 21:1451-1459.
23. May K.F., Roychowdhury S., Bhatt D., et al. Anti-human CTLA-4 monoclonal antibody promotes expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies. Blood 2005, 105:1114-1120.
24. Read S., Greenwald R., Izcue A., et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006, 177:4376-4383.
25. Rezvani K., Mielke S., Ahmadzadeh M., et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 2006, 108:1291-1297.
26. Zorn E. CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol 2006, 16:150-159.
27. Clark F.J., Gregg R., Piper K., et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004, 103:2410-2416.
28. Miura Y., Thobum C.J., Bright E.C., et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 2004, 104:2187-2193.
29. Rezvani A.R., Storb R.F. Separation of graft-vs-tumor effects from graft-vs-host disease in allogeneic hematopoietic cell transplantation. J Autoimmun 2008, 30:172-179.
30. Bashey A., Medina B., Corringham S., et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1581-1588.
31. Baecher-Allan C., Brown J.A., Freeman G.J., et al. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001, 167:1245-1253.
32. Weber J., Thompson J.A., Hamid O., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15:5591-5598.
33. Camacho L.H., Antonia S., Sosman J., et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009, 27:1075-1081.
34. Weber J.S., O'Day S., Urba W., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008, 26:5950-5956.
35. Atanackovic D., Cao Y., Luetkens T., et al. CD4+CD25+FOXP3+ T regulatory cells reconstitution and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Haematologica 2008, 93:423-430.
36. Mielke S., Rezvani K., Savani B.N., et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease. Blood 2007, 110:1689-1697.
37. Wolchok J.D., Neyns B., Linette G., et al. Ipilimumab monotherapy in patients with pretreated advanced melonoma: a randomized, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164.
38. Allen S.E., Crome S.Q., Crellin N.K., et al. Activation-induced FOXP3 in human T effector cells dose not suppress proliferation or cytokine production. Int Immunol 2007, 19:345-354.
39. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen 4. J Clin Oncol 2005, 23:6043-6053.
40. Hersh E.M., O'Day S.J., Powderly J., et al. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Invest New Drugs 2010, In Press.
41. Wang X.B., Zheng C.Y., Giscombe R., et al. Regulation of surface and intracellular CTLA-4 on human peripheral T cells. Scand J Immunol 2001, 54:453-458.
42. Movva S., Verschraegen C. The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab (MDX-010), a novel treatment strategy in cancer treatment. Expert Opin Biol Ther 2009, 9:231-241.
43. Peggs K.S., Quezada S.A., Chambers C.A., et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206:1717-1725.